SAN FRANCISCO -- Herculean efforts by scientists and physicians around the world have resulted more than 50 experimental COVID-19 vaccines currently in global clinical trials. The focus in the U.S.
Shares of Moderna (MRNA), Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt future mRNA vaccine development under the ...
They aren't just "pandemic stocks." ...
While COVID-19 vaccines by Pfizer and Moderna have been authorized for emergency use, more are in development by other pharmaceutical companies. To find out if they work, they need volunteers. Carla ...
AstraZeneca is the latest drugmaker to announce promising Phase 3 trial results from its COVID-19 vaccine candidate. On Monday, AstraZeneca said its two-shot vaccine candidate has been 90% effective ...
Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...